Metered-dose inhalers (pMDIs) for the relief of asthma and chronic obstructive pulmonary disease (COPD) are gaining more attention in conversations about sustainability due to their overall carbon footprint.
This panel discussion brought together some of the leading opinions on this multi-faceted challenge to discuss the challenges we face today and will encounter tomorrow. Topics discussed included the importance of reviewing lessons learned from the transition from CFCs, a review of the current use of pMDIs in the treatment of asthma, the challenges associated with a transition to IPRs, and the need for a collaborative approach in their development. It also summarizes the complex regulatory hurdles, challenges faced by formulation scientists, policy makers and the economics of switching to low GWP propellants. Finally, panelists reviewed the benefits of low-carbon inhalers and the importance of patient choice and preference, which could ultimately weigh heavily on patient compliance and adherence to their asthma treatment. and COPD.
Professor Omar Usmani
Dr. John Pritchard
Dr Jag Shur